(Q33364151)

26 July 2017

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience (English)

1 reference

26 July 2017

J Cortes

7

1 reference

ORCID Public Data File 2021

Issa F Khouri

3

object named as

I Khouri

1 reference

26 July 2017

A-M Tsimberidou

1

1 reference

26 July 2017

F J Giles

2

1 reference

26 July 2017

C Bueso-Ramos

4

1 reference

26 July 2017

S Pilat

5

1 reference

26 July 2017

D A Thomas

6

1 reference

26 July 2017

R Kurzrock

8

1 reference

26 July 2017

1 January 2005

1 reference

26 July 2017

1 reference

26 July 2017

16

1 reference

26 July 2017

1

1 reference

26 July 2017

139-145

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

26 July 2017

1 reference

Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

Pilot study of low-dose interleukin-11 in patients with bone marrow failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

A pilot study of rhuIL-11 treatment of refractory ITP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low- over high-dose administration in selected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

Phase I study of recombinant human interleukin-3 in patients with bone marrow failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

Targeted therapies in myelodysplastic syndromes: ASH 2003 review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

Very low doses of GM-CSF administered alone or with erythropoietin in a plastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI007

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDI007

1 reference

26 July 2017

1 reference